Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels (hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxiainduced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.
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Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels (hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxiainduced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.
Oncogene ( There is experimental evidence that the tumor microenvironment affects both the malignant progression of transformed cells and their responsiveness to chemoand radiotherapy (Brown and Giaccia, 1998; Vaupel et al., 2001) . Hypoxia may influence tumor biology in opposing ways: it is toxic as a stress; but on the other hand, hypoxic solid tumors contain viable cells, which are particularly resistant to treatment and contribute to disease relapse. Indeed, hypoxia is rapidly toxic in most cell types as it can induce necrosis or apoptosis in normal or in transformed cells (Yamaguchi et al., 2001; Zhu et al., 2002) . Cell death is particularly prominent in the zones farthest from the tumor vasculature, where hypoxia stimulates apoptosis (Graeber et al., 1996) . Several studies showed that poor O 2 supply resulted in p53-dependent programmed cell death (Graeber et al., 1994) . However, hypoxia may also be involved in the development of a more aggressive phenotype and contribute to metastasis. In experimental tumors, hypoxia can provide a selective pressure for the expansion of oncogenically transformed cell populations with a reduced apoptotic response to hypoxia as well as to chemotherapeutic agents (Graeber et al., 1996; Kim et al., 1997) . The protective effect of hypoxia against radio-or chemotherapy-induced cytotoxicity has been extensively explored (Ogiso et al., 2000; Vaupel et al., 2001; Achison and Hupp, 2003) . Moreover, poor vascularization impairs chemotherapeutic compound delivery by constricted blood vessels and hypoxic cancer cells distant from blood vessels are exposed to low drug concentration. Therefore, we investigated the effect of low daunomycin concentrations on hypoxia-induced apoptosis in HCT116 colorectal adenocarcinoma cells.
HCT116 human colorectal adenocarcinoma cells were tested for viability in severe hypoxia. Hypoxic cells were grown in a conditioned atmosphere where O 2 was maintained below 0.1%. Cell viability experiment revealed that only 14.2% of HCT116 hypoxic cells were still alive after 72 h as compared to normoxic controls ( Figure 1a) . Surprisingly, cotreatment of these cells with very low daunomycin concentrations protected them against hypoxia-induced toxicity. Indeed, 81.2% of cells cotreated with 0.01 mM of daunomycin were still alive after 3 days of hypoxia (P ¼ 0.0005). Similarly, following 48 h of daunomycin and hypoxia, cells replated in normoxia could grow again while cells exposed to hypoxia alone died (data not shown). This 'protective effect' is concentration dependent and was less pronounced with higher daunomycin concentrations (68% of hypoxic cell viability with 0.05 mM daunomycin; and 44.5% with 0.1 mM daunomycin). Indeed, daunomycin intrinsic cytotoxicity at these higher concentrations reduced HCT116 cell viability in normoxic conditions ( Figure 1a) .
As hypoxia is a well-known inducer of apoptosis, cell extracts from hypoxic cells were analysed for PARP and caspase-3 cleavage and activation (Figure 1b ; top and bottom panels, respectively). Caspase-3 activation and PARP cleavage were observed after 48 or 72 h of hypoxia ( Figure 1b , top and bottom panels, lanes 8 and 9). However, hypoxic HCT116 cells did not undergo apoptosis in the presence of daunomycin, (0.01 mM) as in these conditions, we could not observe any caspase-3 activation or PARP cleavage (Figure 1b ; top and bottom panels, lanes 11 and 12).
Several groups have previously demonstrated that multiple pathways can stabilize p53 in response to different forms of stress (Ashcroft et al., 2000) . p53 activation by DNA damage is followed by increased synthesis of downstream effector proteins. Hypoxic stress, like DNA damage, induces p53 protein accumulation and p53-dependent apoptosis in transformed cells (Koumenis et al., 2001) , but several reports indicated that hypoxia-induced p53 has lost its transactivation potential and rather behaves as a transcriptional repressor in tumor cells. To address p53 expression and activity in our experimental model, nuclear and total protein extracts were prepared after 24, 48, and 72 h of hypoxia or hypoxia plus daunomycin treatment, and expressions of p53 and of two p53-responsive proteins, p21 and Bax, were investigated by Western blot analysis.
Although hypoxia induced a strong p53 accumulation in HCT116 cells (Figure 2 Since transition between apoptotic cell death and proliferation in stress conditions is regulated at cell cycle checkpoints, we determined whether enhanced p21 expression induced a cell cycle arrest that prevented hypoxia-induced apoptosis. The cell cycle parameters were thus monitored under hypoxic conditions in the presence or absence of low daunomycin concentrations. Hypoxia led to an increased number of cells in S phase and ultimately to apoptosis (Figure 3a, third panel) . Simultaneous daunomycin treatment (0.01 mM) restored cell cycle progression after a transient accumulation in S phase (Figure 3a, fourth panel) . These data indicate that daunomycin releases cells from hypoxia-induced S-phase arrest.
To investigate whether p21 expression was required for the daunomycin-mediated protective effect, p21-deficient HCT116 cells (HCT116 p21À/À) were tested for viability after 3 days of hypoxia in the presence or absence of daunomycin (Figure 3b and c) . HCT116 p21À/À cells were sensitive to hypoxia-induced apoptosis and were protected, similarly to the wild-type cells, by treatment with 0.01 mM of daunomycin (Figure 3c ; P ¼ 0.003). p21 is effectively not expressed in HCT116 p21À/À cells as demonstrated by Western blotting (Figure 3b, top panel lanes 1-10) . Therefore, p21 did not play any major role in the daunomycin-induced protective effect.
Hypoxia influences a variety of signal transduction pathways, including MAP kinases (Erk, JNK, and p38) and PI3K/Akt kinases. Akt is a serine-threonine kinase involved in proliferative, metabolic, and apoptotic pathways and is critical for cell survival (Datta et al., 1999; Nicholson and Anderson, 2002) . Activated phospho-Akt (P-Akt) has been shown to protect normal and tumoral cells against hypoxia and p53-induced apoptosis (Ogawara et al., 2002) . Our data showed that An important if not dominant mechanism for phospho-Akt-induced protection comes from its ability to block the activation of Bad-dependent cell death pathway. Akt-induced Bad phosphorylation inactivates Bad ability to form heterodimers with antiapoptotic Bcl-2 proteins, a step thought to be prominent in Bad proapoptotic effects (Datta et al., 1997; del Peso et al., 1997) .
Phospho-Bad analysis by Western blotting correlated Akt and Bad phosphorylation. Indeed, while hypoxia did not induce Bad phosphorylation in HCT116 cells, we observed a progressive Bad phosphorylation when hypoxic cells were treated with low daunomycin concentration (Figure 4b, top panel, lanes 5-7) . Moreover, cell treatment with LY 294002 abolished Bad phosphorylation (Figure 4b , top panel, lanes 8-10 and 11-13), as previously described (Datta et al., 1997) , thus confirming that Bad phosphorylation was Akt dependent in our model.
Although hypoxia is toxic for most cell types, numerous studies report that hypoxia induces tumor cell drug resistance through various mechanisms (Sanna and Rofstad, 1994; Teicher, 1994; Tomida and Tsuruo, 1999) . Poor vascularization impairs chemotherapeutic compound delivery and cancer cells distant from blood vessels (hypoxic cells) are exposed to lower drug concentration. However, little was known about the effect of low drug concentrations on hypoxia-induced apoptosis. In this study, we report that low concentrations of daunomycin, a common anticancer agent, inhibit hypoxia-induced apoptosis in HCT116 colorectal adenocarcinoma cells. Hypoxia triggered p53 accumulation without induction of its responsive genes, while daunomycin-induced protection correlated with reduced p53 and restored p21 expression.
Controversial results have been reported on p53 involvement in hypoxia-induced apoptosis. Achison and Hupp (2003) paradoxically showed that p53 loss sensitized HCT116 cells to hypoxia-induced cell death and that hypoxia attenuated p53 activation by 5-fluorouracile. Conversely, in our study, p53-accelerated degradation seems to be linked to daunomycin cytoprotection. Experimental differences may account for these discording results. In Achison's study, cells were exposed to 1% of O 2 , while we lowered the oxygen concentration to o 0.1% O 2 reaching severe hypoxia. Our results are in agreement with other studies. Indeed, HCT116 p53À/À cells have lost their ability to undergo apoptosis under hypoxia (Yu et al., 2002) , while only severe hypoxia induces p53-dependent apoptosis (Koumenis et al., 2001) .
All these studies agree that hypoxia-induced p53 is not transcriptionally active. Indeed, Koumenis et al. Daunomycin inhibits hypoxia-induced apoptosis C Lechanteur et al demonstrated that, in contrast to DNA damage, hypoxia fails to induce endogenous downstream p53-regulated mRNAs and proteins despite p53 accumulation and our results showed that the expression of the p53-responsive genes p21 and bax is not induced in HCT116 hypoxic cells. Despite a lower p53 expression, daunomycin treatment restored bax and p21 induction under hypoxia, suggesting a restoration of p53 transcriptional activity in hypoxic cells as previously described with doxorubicin, another topoisomerase II inhibitor (Koumenis et al., 2001) . However, in the referred report, doxorubicine induced apoptosis by itself and the addition of doxorubicine prior to hypoxic treatment generated a substantial increase in the apoptotic rates. Indeed, these authors used cytotoxic doxorubicine concentrations, while we worked with low nontoxic concentrations.
Recent papers have focused on an antiapoptotic role of p21 in several cellular models indicating that the choice between growth arrest and apoptosis in HCT116 colorectal cancer cells can be modulated by p21 (Yu et al., 2003) . However, in our study, p21 did not have a major role in the daunomycin protective effect as p21 disruption in HCT116 cells (HCT116 p21À/À) did not modify cell response to hypoxia and daunomycin. PI3K/Akt pathway seems implicated in the protective effect observed in our experimental conditions. Beneficial effects of Akt activation against hypoxic or ischemic insults have been described in cardiomyocytes and astrocytes (Ruscher et al., 2002; Chao et al., 2003) . Although there can be little doubt that PKB/Akt promotes cell survival, the mechanisms involved have only recently begun to emerge. In addition to influencing the transcription of pro-and antiapoptotic genes, numerous studies indicate that PKB/Akt promotes survival by directly phosphorylating key regulators of the apoptotic cascade (Datta et al., 1999; Nicholson and Anderson, 2002) . Bad, a member of the Bcl-2 family, which promotes apoptosis by binding to and antagonizing the action of the prosurvival members of the family such as Bcl-2 or Bcl-Xl, can be phosphorylated and inhibited by Akt. Indeed, S136 phosphorylation promotes the sequestration of Bad by 14-3-3 proteins in the cytosol, thus preventing Bad from interacting with Bcl-2 or Bcl-Xl (Datta et al., 1997; del Peso et al., 1997) . The biological importance of Bad phosphorylation on Ser 136 in promoting survival has been demonstrated after several stress signals. For example, Hirai et al. (2004) demonstrated that Bad phosphorylation by Akt in brain slices prevented cytochrome c-associated apoptosis after hypoxia. NF-kB could also be induced by Akt activation. However, we do not have any evidence that NF-kB plays a role in Akt-dependent cytoprotective effect as this activity is preserved in HCT116 cells stably expressing an NF-kB superrepressor (data not shown).
Our data indicate that low daunomycin concentrations induced Bax expression in hypoxic cells but inhibited apoptosis. This observation is indeed surprising and different hypotheses could possibly explain it. As mentioned, Akt-dependent Bad phosphorylation promotes its sequestration in the cytosol. The induction of apoptosis requires a positive ratio between proapoptotic and antiapoptotic members of the Bcl-2 family. Possibly, Bax increased expression is not sufficient to induce apoptosis in the absence of mitochondrial Bad. Alternatively, Akt could induce the expression of apoptosis inhibitors acting downstream of Bax. Indeed, data suggesting that Akt may influence post-mitochondrial events have been reported as Akt was shown to inhibit the activation of caspase-3 and -9 by released cytochrome c through unidentified cytosolic factors (Nicholson and Anderson, 2002) . Finally, it is not clear whether Bax is really involved in hypoxia-induced apoptosis and Bax induction is not sufficient for p53-induced apoptosis (Sakamuro et al., 1997) .
To our knowledge, this is the first study reporting that daunomycin prevents hypoxia-induced apoptosis through activation of survival pathways, thus indicating a novel mechanism explaining that cancer cells can resist to a natural cytotoxic stress. Moreover, some reports indicate that other drugs such as traztuzumab, tamoxifen, or doxorubicin could also activate the PI3K/Akt pathway leading to resistance to these drugs (Plo et al., 1999; Clark et al., 2002) and possibly also, as suggested by our data, to hypoxia-induced apoptosis. The ability to tolerate hypoxia and withstand apoptosis may be required for tumor progression. PKB/Akt, with its critical role in cell survival, may have an important function in adaptation to these adverse environmental changes.
While it has been widely reported that cancer cell hypoxia can lead to tumor resistance to chemotherapy and radiotherapy, our data indicate that in some cancer cells, the administration of a chemotherapy could favor the resistance of poorly vacularized tumors to hypoxia. Therefore, it is quite possible that chemotherapy could promote the survival of hypoxia-exposed cancer cells and thus select such cells, thereby facilitating subsequent cancer relapse. If such data could be confirmed in other models, it would strongly support the administration of oxygenation-boosting agents simultaneously with chemotherapy. Alternatively, inhibition of the PI3K/Akt pathway could prevent the cytoprotective effect of low local drug concentrations as suggested by a gene therapy study demonstrating that in vivo expression of PTEN in a model of the human bladder suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin (Tanaka and Grossman, 2003) .
